Latest news about Abbott
Abbott
26,065.00
-150.00(-0.57%)
Company Performance:
View Company Insights1D-0.57%
1M-6.22%
6M-7.03%
1Y-16.00%
5Y+57.27%
More news about Abbott
13May 26
Abbott India Limited Issues Postal Ballot Notice for Appointment of Mr. James Wenner and Mr. Neeraj Jain to Its Board
Abbott India Limited has issued a Postal Ballot Notice dated April 22, 2026, seeking shareholder approval for the appointment of Mr. James Wenner (DIN: 11650998) as Non-Executive Director effective April 23, 2026, and Mr. Neeraj Jain (DIN: 00348591) as Independent Director for 3 (three) consecutive years effective April 25, 2026. The notice was dispatched electronically on May 13, 2026, to members on record as on the Cut-Off Date of May 8, 2026. Remote e-voting will be open from 9.00 a.m. (IST) on May 18, 2026, to 5.00 p.m. (IST) on June 16, 2026, with results to be declared not later than 5.00 p.m. (IST) on June 18, 2026. KFin Technologies Limited has been engaged as the e-voting service provider and Registrar and Transfer Agent for this process.
22Apr 26
Abbott India Board Changes: New Directors, Goa Plant Leadership
Abbott India Limited announced comprehensive board and management restructuring following its April 22, 2026 board meeting. The changes include the cessation of Ms. Anisha Motwani's directorship, resignation of Ms. Alison Davies, and appointments of Mr. Neeraj Jain as Independent Director and Mr. James Wenner as Non-Executive Director. Additionally, Mr. Amol Metkar will succeed Mr. Tushar Singh as Plant Director - Goa effective June 1, 2026. All appointments require shareholder approval through postal ballot.
15Apr 26
JPMorgan Downgrades Abbott India to Neutral with ₹27,500 Target Price Amid Strategic Concerns
JPMorgan has downgraded Abbott India to Neutral with a ₹27,500 target price, citing multiple strategic challenges including limited new launches, Mixtard phase-out, and GLP-1 therapy risks. The downgrade also reflects concerns over leadership instability following three MD resignations and a subdued growth outlook. Despite high FY27-28 valuations of 31x/28x, JPMorgan cut its target multiple from 37x to 30x to align with slower-growth MNC pharma peers.
08Apr 26
Abbott India Limited Submits Certificate Under SEBI Depositories Regulations for Q4FY26
Abbott India Limited submitted its quarterly certificate under SEBI Depositories Regulations for Q4FY26 quarter ended March 31, 2026. The certificate, issued by registrar KFin Technologies Limited and submitted to BSE on April 8, 2026, confirms compliance with dematerialization requirements and proper handling of securities during the quarter.
27Feb 26
Abbott India Partners With Novo Nordisk to Launch Extensor® for Diabetes Care
Abbott India has announced a strategic partnership with Novo Nordisk India to launch Extensor® (semaglutide injection) for type 2 diabetes management. This collaboration combines Novo Nordisk's GLP-1 expertise with Abbott's distribution network to expand access to advanced diabetes therapy across India, targeting the country's growing diabetes burden of over 100 million people.
04Feb 26
Abbott India Limited Schedules Board Meeting for February 12, 2026 to Review Q3FY26 Financial Results
Abbott India Limited has scheduled its Board of Directors meeting for February 12, 2026, to consider and approve unaudited financial results for the quarter and nine months ended December 31, 2025. The meeting notification was filed under SEBI LODR Regulation 29(1)(a), with the company's trading window closed from January 1, 2026, and set to reopen 48 hours after results declaration in compliance with insider trading regulations.
03Feb 26
ABB India Executes Rs. 69.64 Crore Block Trade on NSE
ABB India Limited executed a significant block trade on NSE worth Rs. 69.64 crores, involving approximately 121,882 shares at Rs. 5713.50 per share. The substantial transaction value indicates meaningful institutional investor activity and reflects strategic portfolio movements in the engineering and technology company's stock.
22Jan 26
Abbott Shares Plunge 8% Following Q4 Revenue Miss and Weak Q1 Guidance
Abbott Laboratories stock dropped over 8% following disappointing Q4 results with revenue of $11.5 billion missing the $11.8 billion target and weak Q1 guidance of $1.12-$1.18 EPS versus $1.19 consensus. The nutrition segment particularly underperformed at $1.9 billion against $2.19 billion expectations due to competitive pressures and rising production costs. Medical equipment sales met expectations at $5.67 billion, while the company provided full-year adjusted profit guidance of $5.55-$5.80 and announced a $21 billion acquisition of Exact Sciences Corp.
21Jan 26
ABB Targets Higher India Revenue Share Before 2030 as Energy Demand Surges
ABB CEO Morten Wierod announced plans to increase India's contribution to global revenues before 2030, aiming to elevate the country from fourth to third-largest market position. The strategy is driven by India's leadership in energy expansion, rising electricity demand, and the country's role as a strategic manufacturing and export hub. ABB is expanding manufacturing capacity, investing in R&D, and leveraging automation solutions to manage growing power demand across industrial and commercial sectors.
20Jan 26
ABB India Completes Critical BPCL Pipeline Upgrade with Zero Downtime
ABB India Limited has successfully completed a major pipeline infrastructure upgrade for BPCL, achieving zero operational downtime during the transition. The project enhances national energy security through improved cybersecurity measures and system reliability upgrades. This achievement demonstrates ABB India's technical expertise in managing critical energy infrastructure modernization projects.
19Jan 26
ABB India Dispatches First Locally Made Wind Power Converter From Nelamangala Facility
ABB India has dispatched its first locally manufactured wind power converter from its Nelamangala facility, marking a significant manufacturing milestone. This achievement follows the company's acquisition of Gamesa Electric's power electronics business, enabling ABB India to establish domestic production capabilities for wind power conversion equipment.
31Dec 25
Abbott India Limited Receives ₹2.40 Crore GST Penalty Order for Input Tax Credit Disallowance
Abbott India Limited has received a ₹2.40 crore GST penalty order from Mumbai East tax authorities for Input Tax Credit disallowance covering financial years 2018-19, 2019-20, 2021-22, and 2023-24. The company received the order on December 30, 2025, and plans to file an appeal, stating the demand is not maintainable. Abbott India expects no material impact on its financial operations from this penalty order.
24Dec 25
Abbott India Announces Board Changes for 2026
Abbott India Limited has announced significant changes to its board. Mr. Ambati Venu will resign as Director effective December 31, 2025, to pursue an external career opportunity. The company has approved the appointment of Mr. Vivek Mohan as Additional Non-Executive Director, effective January 1, 2026. Mohan brings extensive experience within Abbott, including his upcoming role as Abbott's Vice President, Established Pharmaceuticals, India. The company will seek shareholder approval for Mohan's appointment through a Postal Ballot Notice.
25Nov 25
Abbott India Announces Key Leadership Changes in HR Department
Abbott India Limited has announced the appointment of Ms. Vinutha Mufti as the new Director of Business Human Resources, effective December 16, 2025. She will replace Mr. Rajan Kalantre, who is transitioning to another Abbott affiliate. Ms. Mufti, with over 20 years of HR experience, has been with Abbott since 2015, holding various senior roles across the company's Pharmaceuticals and Nutrition businesses. Her appointment is expected to bring fresh perspectives to Abbott India's HR strategies, particularly in areas of managerial effectiveness, diversity, equity, and inclusion, and talent management.
24Nov 25
Abbott India Appoints New Managing Director
Abbott India Limited has announced the appointment of Ambati Venu as its new Managing Director, effective May 15, 2023, for a five-year term, subject to regulatory approvals. Venu, with over 29 years of experience in the pharmaceutical industry, previously served as Abbott India's Managing Director from 2016 to 2020 and most recently held the position of Group Vice President and Head of Established Pharmaceuticals Division for Abbott's global operations.
06Nov 25
ABB India Q3 Results: Revenue Rises 13.7% Despite Profit Decline
Abbott's Q3 FY2023 results show revenue growth of 13.7% to ₹3,310.00 crore, driven by strong performance in electrification and automation segments. However, net profit declined by 7.3% to ₹409.00 crore, falling short of analyst estimates. EBITDA decreased by 7.4% to ₹500.00 crore, with operating margin contracting to 15.1% from 18.5% year-on-year. The company faced challenges including cost pressures and an unfavorable product mix. New orders in the capital goods sector declined by approximately 20% year-on-year, excluding large one-off deals, indicating potential future headwinds.
28Oct 25
ABB India Boosts Local Drive Production with 25% Capacity Increase at Bengaluru Plant
ABB India has launched new variable speed drive modules at its Peenya factory in Bengaluru, increasing production capacity by 25% and reducing delivery times by up to 40%. The expansion features integrated robotics for automated production, catering to industries such as buildings, data centers, water, cement, and metals. This milestone marks two decades of drives production in India for ABB, following a recent ₹173.55 crore order for wind turbine converters from Siemens Gamesa Renewable Power.
15Oct 25
Abbott India Shareholders Approve Appointment of Darshan Gada as Director
Abbott India Limited concluded a postal ballot through e-voting, resulting in shareholders' approval of Darshan Gada's appointment as Director. The e-voting period ended on October 14, 2025, at 5:00 PM, with the resolution approved on the same day. Gada's appointment is effective from August 18, 2025. The company, listed under scrip code 500488 on BSE, disclosed the voting results in compliance with SEBI regulations.
25Sept 25
ABB India Shares Slump 35% in 12 Months Amid Operational Challenges
ABB India's stock has declined over 35% in the past year, underperforming peers like Siemens and Cummins India. The company faces operational challenges including sluggish decision-making, soft large-ticket business, margin pressures, and revenue shortfalls. Current P/E ratio is 57, a 23% discount to its 5-year average. Despite challenges, some analysts maintain cautious optimism, citing potential for faster order conversion and stronger project pipeline. Market sentiment suggests range-bound growth in the near term.
11Sept 25
Abbott India Seeks Shareholder Approval for Darshan Gada's Director Appointment
Abbott India Limited has initiated a postal ballot to appoint Darshan Gada as a Non-Executive Director. Gada, a 43-year-old Chartered Accountant with 21 years of finance experience, currently serves as Regional Finance Director at Abbott Healthcare Private Limited. The e-voting period is from September 15 to October 14, 2025, with results to be declared by October 16, 2025. Shareholders can access the Postal Ballot Notice on the company's website and KFin Technologies' e-voting platform.
29Aug 25
ABB India Secures ₹174 Crore Wind Turbine Converter Order, Reports Mixed Q3 Results
ABB India has won a ₹173.55 crore order from Siemens Gamesa for wind turbine converters and electrical cabinets, to be delivered from January to December 2026. The company's Q3 financial results show a 12.20% increase in revenue to ₹3,175.40 crore, but a 20.50% decrease in net profit to ₹351.70 crore. EBITDA also declined by 27.00% to ₹441.00 crore. Managing Director Sanjeev Sharma attributed the profit decline to forex volatility and one-time factors. Despite mixed results, ABB India's shares traded 0.76% higher at ₹5,039.00 following the order announcement.
26Aug 25
Abbott India Unveils FreeStyle Libre 2 Plus: Advanced Glucose Monitoring Device
Abbott India has introduced the FreeStyle Libre 2 Plus, a next-generation continuous glucose monitoring device for diabetes management. The device offers minute-by-minute glucose readings and customizable alarms for glucose levels outside the target range. This innovation aims to provide users with more precise data for better diabetes management decisions. Pricing and availability details have not been disclosed.
14Aug 25
Abbott India Shareholders Approve All Resolutions at 81st Annual General Meeting
Abbott India Limited held its 81st Annual General Meeting on August 13, 2025, via video conferencing. Shareholders approved all proposed resolutions, including the adoption of financial statements, declaration of a final dividend, reappointment of directors, appointment of secretarial auditors, ratification of cost auditor remuneration, and appointment of Mr. Kartik Rajendran as Director and Managing Director for five years. The voting process, conducted through NSDL, saw overwhelming support for all resolutions, with most receiving over 99% votes in favor. The company promptly submitted voting results and the scrutinizer's report to BSE Limited, demonstrating commitment to transparency and good corporate governance.
12Aug 25
Abbott India Reports Robust Q1 Performance with 11% Revenue Growth
Abbott India Limited announced robust Q1 FY2025 financial results. Revenue increased by 11.6% to ₹1,738.35 crore, while net profit grew 11.5% to ₹365.86 crore. EBITDA rose 14.1% to ₹445 crore, with the EBITDA margin improving to 25.63%. The company also appointed Mr. Darshan Gada as an Additional (Non-Executive) Director, effective August 18, 2025, subject to shareholder approval.
05Aug 25
ABB India Faces Industrial Project Slowdown, Targets 12-15% Profit Margin for 2025
ABB India reported a record order backlog exceeding Rs 10,000 crore, with 90% of business from the domestic market. The company is experiencing cyclical challenges in its systems order segment due to customer delays. Q2 results showed a 20.7% decrease in net profit to Rs 351.70 crore, while revenue grew 12.2% to Rs 3,175.40 crore. EBITDA margin fell to 13% from 19.2%. Despite challenges, ABB India sees strong demand in tier-1, tier-2, and tier-3 markets, particularly in infrastructure, real estate, and data centers. The company aims for 12-15% profit margins by 2025.
04Aug 25
ABB India Q2 Results: Revenue Grows 12% Amid Margin Pressure
ABB India's Q2 results show a 12% revenue growth to ₹3,175.00 crore, meeting expectations. However, profitability declined with EBITDA falling 24% to ₹414.90 crore and net profit decreasing by 21% year-on-year. EBITDA margin dropped to 13% from 19.2%. The company faced significant cost increases across various categories, including a 26% rise in raw material costs. Order inflow declined by 12% to ₹3,036.00 crore, but the order book grew 6% annually, crossing ₹10,000.00 crore. The board approved evaluating the potential incorporation of the Robotics division into a wholly-owned subsidiary. ABB India's stock closed 2.3% lower at ₹5,384.00 following the results.
02Aug 25
ABB India Q2 Profit Drops 21%, Revenue Grows Amid Margin Pressure
ABB India's Q2 financial results show a 12.2% year-over-year revenue increase to Rs 3,175.00 crore, beating estimates. However, net profit fell 21% to Rs 352.00 crore, missing analyst expectations. EBITDA decreased 23.7% to Rs 414.00 crore, with margins contracting from 19.2% to 13.00%. The company declared an interim dividend of Rs 9.77 per share. Despite challenges, 18 out of 31 analysts maintain a 'Buy' rating on the stock.
01Aug 25
Abbott India Pays Rs. 2 Lakh Penalty to RBI for Exceeding Foreign Investment Limits
Abbott India Limited has been penalized Rs. 2 lakh by the Reserve Bank of India for violating foreign exchange laws. The violation occurred when foreign investment in the company exceeded 75% without prior government approval. The RBI issued a Compounding Order on July 31, 2025, concluding the compounding process. Abbott India will deposit the penalty amount and can now receive foreign institutional investments up to the prescribed limit.
16May 25
Abbott India's Q4 Profit Surges, Beats Estimates
Abbott India Ltd reported strong Q4 financial results, surpassing market expectations. Net profit increased by 14.7% to ₹359.00 crore, revenue rose by 9% to ₹1,633.00 crore, and EBITDA grew by 15% to ₹439.00 crore. The company's stock gained nearly 4% following the announcement, reaching ₹31,500.00 per share.
15May 25
Abbott India: Q4 Profit Soars 28%, ₹475 Dividend Proposed
Abbott India's Q4 results show strong growth with net profit up 27.90% to ₹367.00 crore, revenue increasing 11.50% to ₹1,604.60 crore, and EBITDA rising 30.00% with margin expansion to 26.70%. The company has recommended a final dividend of ₹475.00 per share, subject to shareholder approval.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Zydus Life Science
Dr Reddys Laboratories
Lupin
Mankind Pharma
Aurobindo Pharma
Laurus Labs
1,862.90
(+1.34%)
6,787.50
(+0.66%)
4,457.00
(+0.61%)
1,415.70
(+4.73%)
1,085.50
(+1.37%)
1,290.70
(+1.46%)
2,340.00
(-0.49%)
2,538.30
(+5.14%)
1,491.90
(-0.39%)
1,435.90
(+1.63%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
